Glucagon-like peptide-1, or GLP-1, is a hormone the gut releases after a meal. Synthetic peptides that mimic or prolong its activity have been studied intensively for metabolic conditions, but researchers have increasingly turned their attention to the heart. The central question a 2026 systematic review and meta-analysis published in Cureus set out to answer was whether GLP-1 receptor agonist (GLP-1 RA) peptides improve, worsen, or leave unchanged the outcomes of patients living across the full spectrum of heart failure.
Heart failure is not a single disease. It divides broadly into two phenotypes based on how well the heart's main pumping chamber contracts. In heart failure with reduced ejection fraction, the chamber squeezes weakly. In heart failure with preserved ejection fraction, the chamber squeezes normally but stiffens and cannot fill properly. Researchers have suspected these two groups might respond differently to the same treatment, and the new analysis was designed to test that suspicion with pooled randomized evidence.
The research team searched PubMed, the Cochrane CENTRAL database, and ClinicalTrials.gov through February 2026, ultimately including 14 studies. Six were dedicated heart failure trials that enrolled patients specifically because of their heart failure diagnosis. Eight were cardiovascular outcomes trials that reported heart failure as a subgroup analysis rather than a primary focus. Together the studies covered 18,184 participants, making this one of the larger pooled analyses of GLP-1 peptides in a cardiac population.
How the analysis was structured
The investigators defined a primary composite outcome: cardiovascular death combined with a first hospitalization for heart failure. This kind of composite is standard in cardiology research because both events carry serious consequences for patients and both reflect whether a treatment is genuinely protecting the heart.
Secondary outcomes included all-cause mortality, major adverse cardiovascular events (a grouping that typically covers cardiovascular death, non-fatal heart attack, and non-fatal stroke), a patient-reported quality-of-life score called the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), and a physical performance measure called the six-minute walk distance. The team used a statistical approach called restricted maximum likelihood estimation with an adjustment method known by the initials HKSJ, which is generally considered conservative and less likely to produce falsely narrow confidence intervals when trial counts are modest.
The primary composite outcome
For the main combined endpoint of cardiovascular death plus first heart failure hospitalization, GLP-1 RA peptides produced a hazard ratio of 0.86, meaning roughly a 14 percent lower rate of the composite compared with placebo. The 95 percent confidence interval stretched from 0.73 to 1.01, and the p-value was 0.067. Because that value sits just above the conventional 0.05 threshold, the result is described as not statistically significant. The literature suggests this is a borderline finding rather than a clear positive or clear negative.
There was also meaningful variability across the included studies. The I-squared statistic, which measures how much of the variation in results comes from genuine differences between trials rather than chance, came in at 47 percent. That level of heterogeneity is moderate and signals that the pooled number should not be read as if all 14 trials were measuring the exact same thing in the exact same population.
Mortality and cardiovascular events
The analysis found a statistically significant reduction in all-cause mortality: a hazard ratio of 0.86 with a confidence interval of 0.79 to 0.95 and a p-value of 0.008. On the surface this looks like encouraging evidence. The research team graded this finding as low certainty using the GRADE framework, however, because of an important internal split in the data.
When the investigators separated the six dedicated heart failure trials from the eight cardiovascular outcomes trial subgroups, the mortality signal came almost entirely from the broader cardiovascular outcomes studies. The dedicated heart failure trials, where patients were enrolled specifically because they had heart failure, showed a directional signal toward harm rather than benefit. The authors flag this divergence as a reason for caution. An aggregate number that is pushed upward by one subset of studies while another subset points in the opposite direction tells a more complicated story than a single hazard ratio conveys.
Major adverse cardiovascular events followed a more consistent pattern. GLP-1 RA peptides were associated with a hazard ratio of 0.80 and a confidence interval of 0.69 to 0.93, a statistically significant reduction. This aligns with findings from earlier individual cardiovascular outcomes trials and adds weight to the idea that GLP-1 peptides may have broader cardiac protective properties, at least in populations defined by atherosclerotic risk.
Quality of life and physical function
Two patient-centered measures showed meaningful improvement. The KCCQ-CSS, a validated questionnaire that captures symptoms, physical limitations, and quality of life in heart failure patients, improved by an average of 7.4 points in the GLP-1 RA groups. Researchers generally regard a change of around five points as clinically meaningful, so this result crossed that informal threshold.
The six-minute walk distance, a simple timed walk test widely used in cardiology and pulmonology research, increased by an average of 17.6 meters. These functional and quality-of-life gains were most evident in the subgroup of patients with heart failure with preserved ejection fraction who also had obesity. The literature suggests GLP-1 peptides may reduce body weight and systemic inflammation, and the researchers point to those mechanisms as plausible explanations for the functional improvement seen in this specific phenotype.
The preserved versus reduced ejection fraction divide
One of the clearest patterns to emerge from the pooled analysis is that GLP-1 RA peptides do not appear to behave the same way across both major heart failure subtypes. The signal for quality-of-life and functional benefit clustered in the preserved ejection fraction and obesity phenotype. The dedicated heart failure trials with reduced ejection fraction showed directional harm on mortality, a finding the authors describe carefully but do not dismiss.
This split matters for how researchers interpret the aggregate results. If a beneficial effect in one subtype is averaged together with a possible neutral or harmful effect in another, the pooled number may look reassuring while obscuring important differences. The meta-analysis highlights this as an area where further dedicated randomized evidence is needed before conclusions can be drawn with confidence.
Limitations and what researchers noted
The authors are explicit about the limits of their conclusions. The moderate heterogeneity across studies, the divergence between dedicated heart failure trials and cardiovascular outcomes subgroups, and the low GRADE certainty rating for the all-cause mortality finding all argue for restraint. Subgroup analyses from larger trials are not the same as trials designed with heart failure patients as the primary population, and mixing those two types of evidence introduces uncertainty that statistical adjustment can reduce but not eliminate.
The analysis also covered different GLP-1 RA peptide agents and different dosing regimens, which could contribute to the variability. Early data points at the possibility that receptor engagement, dosing schedule, and patient characteristics interact in ways that a single pooled estimate does not fully capture.
The overall picture the review offers is one of a class of peptides with a plausible cardiovascular mechanism, a robust signal for major adverse cardiac events in higher-risk metabolic populations, meaningful patient-reported improvements in a specific heart failure subtype, and an uncertain mortality story that the research community will need larger, more targeted trials to resolve.
